Literature DB >> 16416212

Opposite association of serum prolactin and survival in patients with colon and rectal carcinomas: influence of preoperative radiotherapy.

Marcos Gutiéerrez De La Barrera1, Belem Trejo, Pedro Luna-Péerez, Fernándo López-Barrera, Gonzalo Martínez De La Escalera, Carmen Clapp.   

Abstract

Prolactin (PRL) is a pleiotropic hormone associated with the progression of various cancers, including colorectal cancer (CRC). Here we investigate whether the association of serum PRL concentration and survival is affected by tumor location and preoperative radiotherapy (PRERT) in patients with CRC cancer. Serum PRL was determined in 82 CRC patients without previous treatment. Patients with PRL concentrations at and above the 75th percentile (high PRL) or below this level (low PRL), had a significant correlation with overall survival determined using the Kaplan-Meier method. In colon cancer, there was an increased risk of mortality when PRL values were at and above the highest quartile (22% vs. 73%; P = 0.01). In contrast, in rectal cancer, high PRL values were associated with a significant overall survival advantage (88% vs. 44%; P = 0.05), which became more significant (100% vs. 34%; P = 0.005) when only rectal cancer patients receiving PRERT were compared. These findings suggest that tumor location and adjuvant radiotherapy influence the association between circulating PRL and survival in CRC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16416212     DOI: 10.1007/s10620-006-3084-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer.

Authors:  T Yamauchi; N Yamauchi; K Ueki; T Sugiyama; H Waki; H Miki; K Tobe; S Matsuda; T Tsushima; T Yamamoto; T Fujita; Y Taketani; M Fukayama; S Kimura; Y Yazaki; R Nagai; T Kadowaki
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

Review 2.  Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects.

Authors:  N Ben-Jonathan; J L Mershon; D L Allen; R W Steinmetz
Journal:  Endocr Rev       Date:  1996-12       Impact factor: 19.871

3.  Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women.

Authors:  S E Hankinson; W C Willett; D S Michaud; J E Manson; G A Colditz; C Longcope; B Rosner; F E Speizer
Journal:  J Natl Cancer Inst       Date:  1999-04-07       Impact factor: 13.506

4.  Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.

Authors:  N A Janjan; V S Khoo; J Abbruzzese; R Pazdur; R Dubrow; K R Cleary; P K Allen; P M Lynch; G Glober; R Wolff; T A Rich; J Skibber
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

Review 5.  Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis.

Authors:  A M Corbacho; G Martínez De La Escalera; C Clapp
Journal:  J Endocrinol       Date:  2002-05       Impact factor: 4.286

Review 6.  Prolactin in autoimmunity and antitumor defence.

Authors:  L Matera; M Mori; M Geuna; S Buttiglieri; G Palestro
Journal:  J Neuroimmunol       Date:  2000-09-01       Impact factor: 3.478

Review 7.  Gender and colorectal cancer.

Authors:  J J DeCosse; S S Ngoi; J S Jacobson; W J Cennerazzo
Journal:  Eur J Cancer Prev       Date:  1993-03       Impact factor: 2.497

8.  Prolactin secreting renal cell carcinoma.

Authors:  T H Stanisic; J Donovan
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

Review 9.  Adjuvant therapy of cancers of the colon and rectum.

Authors:  Leonard B Saltz; Bruce Minsky
Journal:  Surg Clin North Am       Date:  2002-10       Impact factor: 2.741

10.  Different age and sex relationship for cancer of subsites of the large bowel.

Authors:  O M Jensen
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

View more
  3 in total

1.  Prognostic value of prolactin in postoperative colorectal carcinoma.

Authors:  Aman Chauhan; Jacob Kurian; Anjali Kakria; Tanuj Kanchan; Ritesh G Menezes
Journal:  Gastrointest Cancer Res       Date:  2008-09

2.  MCM2 and MCM5 as prognostic markers in colon cancer: a worthwhile approach.

Authors:  Maximilian Burger
Journal:  Dig Dis Sci       Date:  2008-08-21       Impact factor: 3.199

3.  Comparative study of tumor markers in patients with colorectal carcinoma before and after chemotherapy.

Authors:  Atreyee Basu; Shashi Seth; Ashok K Chauhan; Nupur Bansal; Kanchan Arora; Anuradha Mahaur
Journal:  Ann Transl Med       Date:  2016-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.